期刊
FARMACIA
卷 68, 期 3, 页码 547-552出版社
SOC STIINTE FARMACEUTICE ROMANIA
DOI: 10.31925/farmacia.2020.3.22
关键词
coronary heart disease; coenzyme Q(10); atorvastatin; blood lipids
资金
- Scientific Research Project of Heilongjiang Health and Family Planning Commission [2014-191]
The aim of this study was to evaluate the efficacy of coenzyme Q(10) (CoQ(10)) in combination with atorvastatin on coronary heart disease (CHD). In this study there were included 84 patients with CHD and divided into two groups, a control group (42 patients), treated with atorvastatin and an experimental group (42 patients) that received atorvastatin and CoQ(10). CoQ(10) levels, transaminase activities (ALT and AST), blood lipid, cardiac function, and hemodynamic, were measured and evaluated before the treatment and 3 months after the treatment. Both treatments were safe and effective in the clinical management if lipidic imbalance in CHD, but the experimental group had better therapeutic effects. The CoQ(10) level in the experimental group increased after the treatment (p < 0.05), while in the control group decreased significantly (p < 0.05). ALT and AST levels did not changed significantly after the treatment in the experimental group, while in the control group, it was observed a significant increase (p < 0.05). After treatment, the left ventricular diastolic function of the experimental group was improved significantly (p < 0.05). Meanwhile, the left ventricular diastolic function of the control group was also improved to some extent, but the difference was not statistically significant (p > 0.05). In conclusion, CoQ(10) supplementation could avoid the increase of transaminases caused by atorvastatin, and could enhance the lipid-lowering effect of atorvastatin and improve the cardiac function effectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据